Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, posted on X:
“Can SCLC molecular subtypes guide therapy?
1. ASCL1: anti DLL3 based therapy, sensitivity to PARPi
2. Pou2F3: sensitivity to parpi
3 I- Inflamed subtype: sensitivity to IO+
4. NeuroD1: MYC targeting may help, responses observed with Aurora kinase inhibitors.”